Pancreatic Cancer Research

ResearcherShinshu University HospitalActive in the last 2 years

Shigetaka Shimodaira

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6612-6912; OpenAlex author ID A5024838892. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide… Co-author DOI 10.1136/jitc-2024-011426↗
  2. Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable … Co-author DOI 10.1136/jitc-2024-009765↗
  3. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1. Co-author DOI 10.1159/000500359↗
  4. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Last author DOI 10.21873/anticanres.12464↗
  5. Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2018.8961↗
  6. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer. Co-author PMID 28950074↗
  7. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Co-author DOI 10.2217/imt-2016-0031↗
  8. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Co-author DOI 10.1007/s00262-014-1554-7↗
  9. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0314↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeo Koido · 8 shared papers, 2014–2025 · strength 0.81
  2. Haruo Sugiyama · 8 shared papers, 2014–2025 · strength 0.81
  3. Zensho Ito · 4 shared papers, 2018–2025 · strength 0.53
  4. Masayuki Saruta · 4 shared papers, 2018–2025 · strength 0.53
  5. Toshifumi Ohkusa · 3 shared papers, 2019–2025 · strength 0.46
  6. Masato Okamoto · 7 shared papers, 2014–2019 · strength 0.46
  7. Masamori Shimabuku · 2 shared papers, 2024–2025 · strength 0.38
  8. Shin Kan · 3 shared papers, 2014–2024 · strength 0.28
  9. Shintaro Tsukinaga · 2 shared papers, 2014–2024 · strength 0.21
  10. Mikio Kajihara · 3 shared papers, 2014–2019 · strength 0.17
  11. Kazuhiro Nagai · 2 shared papers, 2014–2018 · strength 0.11
  12. Kazuki Takakura · 2 shared papers, 2014–2018 · strength 0.10
  13. Ryu Yanagisawa · 1 shared paper, 2018 · strength 0.08
  14. Sayumi Yoshida · 1 shared paper, 2019 · strength 0.08
  15. Tomoya Kanai · 1 shared paper, 2018 · strength 0.07
  16. Shuichi Fujioka · 1 shared paper, 2018 · strength 0.07
  17. Sumiyuki Nishida · 1 shared paper, 2018 · strength 0.07
  18. Yoshikazu Yonemitsu · 1 shared paper, 2014 · strength 0.04
  19. Masahiro Ogasawara · 1 shared paper, 2014 · strength 0.04
  20. Yuta Shibamoto · 1 shared paper, 2014 · strength 0.04
  21. Yoichi Toyama · 1 shared paper, 2014 · strength 0.03
  22. Hisao Tajiri · 1 shared paper, 2014 · strength 0.03
  23. Sadamu Homma · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.